Orion Corporation has resolved to issue a EUR 150 million fixed rate unsecured bond. The funds will be used for general corporate purposes. The bond matures in six (6) years and pays a coupon of 2.75 percent. The bond will be applied to be listed on NASDAQ OMX Helsinki Ltd.
Pohjola Markets acts as lead manager for the transaction.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
Disclaimer
The information contained in this release shall not constitute an offer to sell securities of Orion Corporation in any jurisdiction. In particular, this release does not constitute an offer to sell securities in the United States. Any securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements.